Reviewing Perspective Therapeutics (CATX) and Its Competitors

Perspective Therapeutics (NYSEAMERICAN:CATX) is one of 84 publicly-traded companies in the “Surgical & medical instruments” industry, but how does it compare to its competitors? We will compare Perspective Therapeutics to related companies based on the strength of its profitability, analyst recommendations, dividends, earnings, valuation, institutional ownership and risk.

Analyst Ratings

This is a summary of recent ratings for Perspective Therapeutics and its competitors, as provided by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Perspective Therapeutics	0	0	8	3	3.27
Perspective Therapeutics Competitors	1341	1940	2268	59	2.19

Perspective Therapeutics currently has a consensus target price of $12.67, indicating a potential upside of 150.33%. As a group, “Surgical & medical instruments” companies have a potential upside of 80.96%. Given Perspective Therapeutics’ stronger consensus rating and higher possible upside, research analysts plainly believe Perspective Therapeutics is more favorable than its competitors.

Valuation and Earnings

This table compares Perspective Therapeutics and its competitors revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Perspective Therapeutics	$1.45 million	-$79.28 million	N/A
Perspective Therapeutics Competitors	$172.70 million	-$17.70 million	-11.08

Perspective Therapeutics’ competitors have higher revenue and earnings than Perspective Therapeutics.

Institutional and Insider Ownership

54.7% of Perspective Therapeutics shares are owned by institutional investors. Comparatively, 41.0% of shares of all “Surgical & medical instruments” companies are owned by institutional investors. 3.7% of Perspective Therapeutics shares are owned by company insiders. Comparatively, 13.9% of shares of all “Surgical & medical instruments” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Risk & Volatility

Perspective Therapeutics has a beta of 1.75, indicating that its stock price is 75% more volatile than the S&P 500. Comparatively, Perspective Therapeutics’ competitors have a beta of 4.29, indicating that their average stock price is 329% more volatile than the S&P 500.

Profitability

This table compares Perspective Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Perspective Therapeutics	-9,841.86%	-40.03%	-33.99%
Perspective Therapeutics Competitors	-1,332.47%	-190.31%	-31.88%

Perspective Therapeutics Company Profile

Perspective Therapeutics, Inc., together with its subsidiaries, develops precision-targeted alpha therapies (TAT) for oncology that treats cancer patients across multiple tumor types comprising metastatic disease. The company discovers, designs, and develop its initial programs candidates consists of VMT-a-NET, that is currently in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2) expressing tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta-emitting therapy; and VMT01, which is currently in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma. Perspective Therapeutics, Inc. has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 1998 and is headquartered in Seattle, Washington.